Dupilumab Skin Barrier Function and Lipidomics Study in Atopic Dermatitis in China
Status:
Not yet recruiting
Trial end date:
2024-03-28
Target enrollment:
Participant gender:
Summary
This is a 16-week, open label, exploratory study designed to investigate dupilumab's effect
on skin barrier function as measured by transepidermal water loss (TEWL) before and after
skin tape stripping. During the first 2 treatment weeks, patients will have 2 on-site
visits/week, followed by one on-site visit/week up to Week 4, one on-site visit every two
weeks from Week 4 to Week 8, and one on-site visit every 4 weeks up to Week 16 End of
Treatment phase visit (EoT) thereafter.
A follow-up visit by phone 4 weeks after the last study assessment at Week 16 will end the
study for each participant (End of Study: EoS). The maximum duration of the study per
participant will be 24 weeks.